These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26260280)

  • 1. Ability of Bottle Cap Color to Facilitate Accurate Patient-Physician Communication Regarding Medication Identity in Patients with Glaucoma.
    Dave P; Villarreal G; Friedman DS; Kahook MY; Ramulu PY
    Ophthalmology; 2015 Dec; 122(12):2373-9. PubMed ID: 26260280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Utility of Cap Color and Bottle Characteristics for Topical Glaucoma Therapy.
    Marando CM; Seibold LK; SooHoo JR; Pantcheva MB; Ramulu PY; Kahook MY
    Ophthalmology; 2015 Dec; 122(12):2577-8. PubMed ID: 26077575
    [No Abstract]   [Full Text] [Related]  

  • 3. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia.
    Al-Jumaian N; Malik R; Khandekar R; Al-Humaidan A; Al-Madany R; Al-Qahtani R; Altowairqi A; Al-Theeb A; Zaman B; Al-Djasim L; Craven ER; Edward DP
    Middle East Afr J Ophthalmol; 2016; 23(4):296-301. PubMed ID: 27994392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating eye drop instillation technique in glaucoma patients.
    Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
    J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study.
    Boland MV; Chang DS; Frazier T; Plyler R; Friedman DS
    JAMA Ophthalmol; 2014 Jul; 132(7):838-44. PubMed ID: 24830878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic glaucoma drop bottle cap colours.
    Hallaji NAE; Trope GE
    Can J Ophthalmol; 2016 Oct; 51(5):392-393. PubMed ID: 27769334
    [No Abstract]   [Full Text] [Related]  

  • 8. Human Factors and Ophthalmic Drug Packaging: Time for a Global Standard.
    Brandt JD
    Ophthalmology; 2015 Dec; 122(12):2368-70. PubMed ID: 26592669
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glaucoma on identification of bottle cap color in ophthalmic medications.
    Paul J; Hammer JD; Akhtari R; Skillings B; Moore DB
    Int J Ophthalmol; 2019; 12(1):169-171. PubMed ID: 30662857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and vision-related quality of life in the early manifest glaucoma trial.
    Hyman LG; Komaroff E; Heijl A; Bengtsson B; Leske MC;
    Ophthalmology; 2005 Sep; 112(9):1505-13. PubMed ID: 16019074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey.
    Newman-Casey PA; Robin AL; Blachley T; Farris K; Heisler M; Resnicow K; Lee PP
    Ophthalmology; 2015 Jul; 122(7):1308-16. PubMed ID: 25912144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the introduction of generic latanoprost on glaucoma medication adherence.
    Stein JD; Shekhawat N; Talwar N; Balkrishnan R
    Ophthalmology; 2015 Apr; 122(4):738-47. PubMed ID: 25680226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity.
    Sleath B; Blalock S; Covert D; Stone JL; Skinner AC; Muir K; Robin AL
    Ophthalmology; 2011 Dec; 118(12):2398-402. PubMed ID: 21856009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy cost considerations for glaucoma.
    Fiscella RG; Green A; Patuszynski DH; Wilensky J
    Am J Ophthalmol; 2003 Jul; 136(1):18-25. PubMed ID: 12834665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of the After-visit Summary in Medication Recall Among Glaucoma Patients.
    Hirabayashi KJ; Pomerantz M; Radell JE; Chadha N; Thomas S; Serle JB
    J Glaucoma; 2020 Jul; 29(7):529-535. PubMed ID: 32332333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of patient perception of glaucomatous visual field loss and its association with disease severity using Amsler grid.
    Fujitani K; Su D; Ghassibi MP; Simonson JL; Liebmann JM; Ritch R; Park SC
    PLoS One; 2017; 12(9):e0184230. PubMed ID: 28949971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients.
    O'Hare F; Jeganathan VS; Rokahr CG; Rogers SL; Crowston JG
    Clin Exp Ophthalmol; 2009 Dec; 37(9):849-54. PubMed ID: 20092593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of glaucoma medications: a 3-year review.
    Vold SD; Riggs WL; Jackimiec J
    J Glaucoma; 2002 Aug; 11(4):354-8. PubMed ID: 12169974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.